Influence of glucocorticoids and growth hormone on insulin sensitivity in humans

Diabetic Medicine

Volumn 30, Issue 6, 2013, Pages 651-663

  Yuen, K C J ^a   Chong, L E ^a   Riddle, M C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GLUCOCORTICOID; GLUCOSE; GLUCOSE TRANSPORTER 4; GROWTH HORMONE; INCRETIN; INSULIN RECEPTOR SUBSTRATE 1; LIPOPROTEIN LIPASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RESISTIN; SOMATOMEDIN C; TRIACYLGLYCEROL;

ACROMEGALY; ADRENAL CORTEX; ARTICLE; CLINICAL PRACTICE; CONTINUOUS INFUSION; CUSHING SYNDROME; DIABETES MELLITUS; FOOD INTAKE; GENETIC TRANSCRIPTION; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOGENOLYSIS; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPOINSULINEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID STORAGE; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; POSTPRANDIAL STATE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ANIMALS; CIRCADIAN RHYTHM; GLUCOCORTICOIDS; GLUCONEOGENESIS; GLUCOSE METABOLISM DISORDERS; GLYCOLYSIS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIVER; MUSCLE, SKELETAL; RECOMBINANT PROTEINS;

EID: 84878101513     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12184     Document Type: Article

References (135)

1. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109Suppl 2: S135-148.
2. Himsworth HP. Diabetes mellitus: its differentiation into insulin sensitive and insulin insensitive types. Lancet 1936; 1: 127-130.
3. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960: 1157-1175.
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
5. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
6. Grundy SM, Brewer HB, . Jr, Cleeman JI, Smith SC, . Jr, Lenfant C, American Heart A et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
8. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
9. Houssay BA, Rodriguez RR, Cardeza AF. Prevention of experimental diabetes with adrenal steroids. Endocrinology 1954; 54: 550-552.
10. Houssay BA. The hypophysis and metabolism. New Eng J Med 1936; 214: 961-985.
11. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
12. Bolli GB, De Feo P, De Cosmo S, Perriello G, Ventura MM, Calcinaro F et al. Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 1984; 33: 1150-1153.
13. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 2003; 46Suppl 1: M2-8.
14. Corpeleijn E, Mensink M, Kooi ME, Roekaerts PM, Saris WH, Blaak EE. Impaired skeletal muscle substrate oxidation in glucose-intolerant men improves after weight loss. Obesity 2008; 16: 1025-1032.
15. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
16. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A et al. Correlation between serum resistin level and adiposity in obese individuals. Obesity Res 2003; 11: 997-1001.
17. Bobbert T, Schwarz F, Fischer-Rosinsky A, Pfeiffer AF, Mohlig M, Mai K et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013; 36: 145-149.
18. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-111.
19. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 2006; 12: 358-362.
20. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-866.
21. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clinical Sci 1999; 96: 513-523.
22. Chavez M, Seeley RJ, Green PK, Wilkinson CW, Schwartz MW, Woods SC. Adrenalectomy increases sensitivity to central insulin. Physiol Behav 1997; 62: 631-634.
23. Yuen KC, McDaniel PA, Riddle MC. Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol 2012; 77: 224-232.
24. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000-1007.
25. Henriksen JE, Alford F, Vaag A, Handberg A, Beck-Nielsen H. Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Metabolism 1999; 48: 1128-1135.
26. Tikkanen MJ, Kuusi T, Nikkila EA, Sane T. Very low density lipoprotein triglyceride kinetics during hepatic lipase suppression by estrogen. Studies on the physiological role of hepatic endothelial lipase. FEBS Let 1985; 181: 160-164.
27. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32Suppl 3: 14-23.
28. Zimmerman T, Horber F, Rodriguez N, Schwenk WF, Haymond MW. Contribution of insulin resistance to catabolic effect of prednisone on leucine metabolism in humans. Diabetes 1989; 38: 1238-1244.
29. Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008; 36: 146-164.
30. Van Raalte DH, Van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011; 34: 412-417.
31. Van Raalte DH, Nofrate V, Bunck MC, Van Iersel T, Elassaiss Schaap J, Nassander UK et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol 2010; 162: 729-735.
32. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997; 40: 1439-1448.
33. Larsson H, Ahren B. Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia 1999; 42: 936-943.
34. Matsumoto K, Yamasaki H, Akazawa S, Sakamaki H, Ishibashi M, Abiru N et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996; 81: 2621-2626.
35. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci USA 1992; 89: 6035-6039.
36. Besse C, Nicod N, Tappy L. Changes in insulin secretion and glucose metabolism induced by dexamethasone in lean and obese females. Obes Res 2005; 13: 306-311.
37. Kauh EA, Mixson LA, Shankar S, McCarthy J, Maridakis V, Morrow L et al. Short-term metabolic effects of prednisone administration in healthy subjects. Diabetes Obes Metab 2011; 13: 1001-1007.
38. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab 2011; 96: 447-453.
39. Wise JK, Hendler R, Felig P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest 1973; 52: 2774-2782.
40. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. J Clin Endocrinol Metab 2012; 97: 1363-1370.
41. Jensen DH, Aaboe K, Henriksen JE, Volund A, Holst JJ, Madsbad S et al. Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Diabetologia 2012; 55: 1406-1416.
42. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
43. Krusenstjerna-Hafstrom T, Clasen BF, Moller N, Jessen N, Pedersen SB, Christiansen JS et al. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. J Clin Endocrinol Metab 2011; 96: 2548-2557.
44. Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 1982; 31: 663-669.
45. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987; 8: 115-131.
46. Press M. Growth hormone and metabolism. Diabetes Metab Rev 1988; 4: 391-414.
47. Coculescu M, Niculescu D, Lichiardopol R, Purice M. Insulin resistance and insulin secretion in non-diabetic acromegalic patients. Exp Clin Endocrinol Diabetes 2007; 115: 308-316.
48. Luft R. Some considerations on the pathogenesis of diabetes mellitus. New Eng J Med 1968; 279: 1086-1092.
49. Serrano-Rios M, Rodriguez Minon JL, Ramos F, Vivanco F. Glucose tolerance in acromegaly: a study of insulin secretion. Isr J Med Sci 1972; 8: 876-877.
50. Bratusch-Marrain PR, Smith D, DeFronzo RA. The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 1982; 55: 973-982.
51. Fowelin J, Attvall S, Von Schenck H, Smith U, Lager I. Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 1991; 34: 500-506.
52. Moller N, Jorgensen JO, Alberti KG, Flyvbjerg A, Schmitz O. Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man. J Clin Endocrinol Metab 1990; 70: 1179-1186.
53. Krusenstjerna-Hafstrom T, Madsen M, Vendelbo MH, Pedersen SB, Christiansen JS, Moller N et al. Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load. PloS One 2011; 6: e19392.
54. Takano A, Haruta T, Iwata M, Usui I, Uno T, Kawahara J et al. Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes. Diabetes 2001; 50: 1891-1900.
55. Moller N, Porksen N, Ovesen P, Alberti KG. Evidence for increased sensitivity of fuel mobilization to growth hormone during short-term fasting in humans. Horm Metab Res 1993; 25: 175-179.
56. Norrelund H. The metabolic role of growth hormone in humans with particular reference to fasting. Growth Horm IGF Res 2005; 15: 95-122.
57. Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992; 74: 1012-1019.
58. Laursen T. Clinical pharmacological aspects of growth hormone administration. Growth Horm IGF Res 2004; 14: 16-44.
59. Moller N, Moller J, Jorgensen JO, Ovesen P, Schmitz O, Alberti KG et al. Impact of 2 weeks high dose growth hormone treatment on basal and insulin stimulated substrate metabolism in humans. Clin Endocrinol 1993; 39: 577-581.
60. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2121-2127.
61. Schlierf G, Dorow E. Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest 1973; 52: 732-740.
62. Hollister LE, Wright A. Diurnal variation of serum lipids. J Atheroscler Res 1965; 5: 445-450.
63. Miles JM, Wooldridge D, Grellner WJ, Windsor S, Isley WL, Klein S et al. Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy. Diabetes 2003; 52: 675-681.
64. Magkos F, Mohammed BS, Patterson BW, Mittendorfer B. Free fatty acid kinetics in the late phase of postexercise recovery: importance of resting fatty acid metabolism and exercise-induced energy deficit. Metabolism 2009; 58: 1248-1255.
65. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
66. Bergman RN, Mittelman SD. Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmaco 1998; 9: 205-221.
67. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
68. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001; 50Suppl 1: S118-121.
69. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-1274.
70. Fielding BA, Frayn KN. Lipoprotein lipase and the disposition of dietary fatty acids. Br J Nutr 1998; 80: 495-502.
71. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res 1994; 35: 177-193.
72. Kennedy B, Elayan H, Ziegler MG. Glucocorticoid induction of epinephrine synthesizing enzyme in rat skeletal muscle and insulin resistance. J Clin Invest 1993; 92: 303-307.
73. Ong JM, Simsolo RB, Saffari B, Kern PA. The regulation of lipoprotein lipase gene expression by dexamethasone in isolated rat adipocytes. Endocrinology 1992; 130: 2310-2316.
74. Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 1988; 81: 968-975.
75. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 2008; 197: 189-204.
76. Boyar RM, Witkin M, Carruth A, Ramsey J. Circadian cortisol secretory rhythms in Cushing's disease. J Clin Endocrinol Metab 1979; 48: 760-765.
77. Semer M, Faria AC, Nery M, Salgado LR, Knoepfelmacher M, Wajchenberg BL et al. Growth hormone pulsatility in active and cured acromegalic subjects. J Clin Endocrinol Metab 1995; 80: 3767-3770.
78. Aimaretti G, Colao A, Corneli G, Pivonello R, MacCario M, Morrison K et al. The study of spontaneous GH secretion after 36-h fasting distinguishes between GH-deficient and normal adults. Clin Endocrinol 1999; 51: 771-777.
79. Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol 2006; 65: 45-50.
80. Molina ME. Chapter 6. Adrenal gland. In: Weitz M, Naglieri C, eds. Endocrine physiology, 3rd edition. New York, NY: McGraw-Hill, 2010.
81. Zhou J, Cidlowski JA. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 2005; 70: 407-417.
82. Fain JN, Dodd A, Novak L. Enzyme regulation in gluconeogenesis and lipogenesis. Relationship of protein synthesis and cyclic AMP to lipolytic action of growth hormone and glucocorticoids. Metabolism 1971; 20: 109-118.
83. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism 2011; 60: 1500-1510.
84. Van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
85. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine reviews 2009; 30: 152-177.
86. Gormsen LC, Nielsen C, Jessen N, Jorgensen JO, Moller N. Time-course effects of physiological free fatty acid surges on insulin sensitivity in humans. Acta Physiol (Oxf) 2011; 201: 349-356.
87. Gravholt CH, Schmitz O, Simonsen L, Bulow J, Christiansen JS, Moller N. Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am J Physiol 1999; 277: E848-854.
88. Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981; 4: 579-585.
89. Touitou Y, Auzeby A, Camus F, Djeridane Y. Daily profiles of salivary and urinary melatonin and steroids in healthy prepubertal boys. J Pediatr Endocrinol Metab 2009; 22: 1009-1015.
90. Bright GM, Melton TW, Rogol AD, Clarke WL. Failure of cortisol blockade to inhibit early morning increases in basal insulin requirements in fasting insulin-dependent diabetics. Diabetes 1980; 29: 662-664.
91. Skor DA, White NH, Thomas L, Shah SD, Cryer PE, Santiago JV. Examination of the role of the pituitary-adrenocortical axis, counterregulatory hormones, and insulin clearance in variable nocturnal insulin requirements in insulin-dependent diabetes. Diabetes 1983; 32: 403-407.
92. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Chale JJ et al. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia 1996; 39: 1498-1504.
93. Pal BR, Matthews DR, Edge JA, Mullis PE, Hindmarsh PC, Dunger DB. The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia. Clin Endocrinol 1993; 38: 93-100.
94. Pal BR, Phillips PE, Matthews DR, Dunger DB. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 542-549.
95. Franek E, Schaefer F, Bergis K, Feneberg R, Ritz E. Abnormal pulsatile secretion of growth hormone in non-insulin-dependent diabetes mellitus. Clin Endocrinol 1997; 47: 471-478.
96. Levy CJ, Kinsley BT, Bajaj M, Simonson DC. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 1998; 21: 1330-1338.
97. Micic D, Macut D, Popovic V, Kendereski A, Sumarac-Dumanovic M, Zoric S et al. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus. Metabolism 1999; 48: 525-530.
98. Atiea JA, Vora JP, Owens DR, Luzio S, Read GF, Walker RF et al. Non-insulin-dependent diabetic patients (NIDDMs) do not demonstrate the dawn phenomenon at presentation. Diabetes Res Clin Pract 1988; 5: 37-44.
99. Carroll MF, Hardy KJ, Burge MR, Schade DS. Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy. Diabetes Technol Ther 2002; 4: 595-605.
100. Butler P, Kryshak E, Rizza R. Mechanism of growth hormone-induced postprandial carbohydrate intolerance in humans. Am J Physiol 1991; 260: E513-520.
101. Bonuccelli S, Muscelli E, Gastaldelli A, Barsotti E, Astiarraga BD, Holst JJ et al. Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. Am J Physiol Endocrinol Metab 2009; 297: E532-537.
102. Hamman L, Hirschman II. Studies on blood sugar. Effects upon the blood sugarof the repeated ingestion of glucose. Johns Hopkins Hospital Bulletin 1919; 344: 306-308.
103. Staub H. Untersuchungen uber den Zuckerstoffwechsel des Menschen. I Mitteilung Z Klin Med 1921; 91: 44-60.
104. Traugott K. Uber das Verhalten des Blutzucher Spiegels bei wiederholter und verschiedener Art enteraler Zuckerzufuhr und dessen. Bedeutung für die Leberfunction Klin Woch 1 1922; i: 892-894.
105. Streeten DH, Gerstein MM, Woolfolk D, Doisy RJ. Measurement of glucose disposal rates in normal and diabetic human subjects after repeated intravenous injections of glucose. J Clin Endocrinol Metab 1964; 24: 761-774.
106. Abraira C, Graham LA, Lawrence AM. Absence of facilitated glucose disposal (Staub-Traugott effect) in subjects with hypopituitarism. Metabolism 1975; 24: 1145-1155.
107. Soskin S, Mirsky IA, Zimmerman LM, Heller RC. Indispensability of the hypophysis to the Staub-Traugott phenomenon. Amer J Physiol 1936; 116: 148.
108. Abraira C, Lawrence AM. Preservation of glucose tolerance and insulin secretory response to repeated glucose levels by the feeding of minimal glucose during prolonged fasting. Metabolism 1981; 30: 1200-1208.
109. Abraira C, Lawrence AM. Improved tolerance to successive glucose loads in acromegaly. Metabolism 1977; 26: 287-293.
110. Wajngot A, Grill V, Efendic S, Cerasi E. The Staub-Traugott effect. Evidence for multifactorial regulation of a physiological function. Scand J Clin Lab Invest 1982; 42: 307-313.
111. Szabo AJ, Maier JJ, Szabo O, Camerini-Davalos RA. Improved glucose disappearance following repeated glucose administration. Serum insulin growth hormone and free fatty acid levels during the Staub-Traugott effect. Diabetes 1969; 18: 232-237.
112. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
113. Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011; 22: 499-506.
114. Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010; 92Suppl 1: 77-81.
115. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006; 29: 81-90.
116. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97: 2039-2049.
117. Meyer G, Hackemann A, Reusch J, Badenhoop K. Nocturnal hypoglycemia identified by a continuous glucose monitoring system in patients with primary adrenal insufficiency (Addison's Disease). Diabetes Technol Ther 2012; 14: 386-388.
118. Takeda N, Yasuda K, Kitabchi AE, Horiya T, Jallepalli P, Miura K. Increased insulin binding of erythrocytes and insulin sensitivity in adrenal insufficiency. Metabolism 1987; 36: 1063-1066.
119. Christiansen JJ, Djurhuus CB, Gravholt CH, Iversen P, Christiansen JS, Schmitz O et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab 2007; 92: 3553-3559.
120. Bolinder J, Ostman J, Werner S, Arner P. Insulin action in human adipose tissue in acromegaly. J Clin Invest 1986; 77: 1201-1206.
121. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986; 250: E269-273.
122. Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 2010; 95: 3648-3656.
123. Higham CE, Rowles S, Russell-Jones D, Umpleby AM, Trainer PJ. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 2009; 94: 2459-2463.
124. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol 2003; 59: 492-499.
125. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002; 25: 502-507.
126. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New Eng J Med 1989; 321: 1797-1803.
127. O'Neal DN, Kalfas A, Dunning PL, Christopher MJ, Sawyer SD, Ward GM et al. The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J Clin Endocrinol Metab 1994; 79: 975-983.
128. Hew FL, Koschmann M, Christopher M, Rantzau C, Vaag A, Ward G et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 1996; 81: 555-564.
129. Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995; 80: 153-159.
130. Jorgensen JO, Krag M, Jessen N, Norrelund H, Vestergaard ET, Moller N et al. Growth hormone and glucose homeostasis. Horm Res 2004; 62Suppl 3: 51-55.
131. Salomon F, Cuneo RC, Umpleby AM, Sonksen PH. Glucose and fat metabolism in adults with growth hormone deficiency. Clin Endocrinol 1994; 41: 315-322.
132. Yuen K, Frystyk J, Umpleby M, Fryklund L, Dunger D. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults. J Clin Endocrinol Metab 2004; 89: 3956-3964.
133. Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol 2005; 63: 428-436.
134. Lucidi P, Lauteri M, Laureti S, Celleno R, Santoni S, Volpi E et al. A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 1998; 83: 353-357.
135. Yuen KC, Dunger DB. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab 2007; 9: 11-22.